Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | BDKRB1 | P46663 | 17/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22563748 | 1.00 | ALDH1A1 (0.66) | ALDH1A1POLBBDKRB1 | |
| SCHEMBL15599428 | 0.93 | ALDH1A1 (0.65) | ALDH1A1POLBBDKRB1 | |
| SCHEMBL4424964 | 0.89 | ALDH1A1 (0.76) | ALDH1A1POLBBDKRB1 | |
| SCHEMBL22563749 | 0.86 | ALDH1A1 (0.77) | ALDH1A1POLBBDKRB1 | |
| SCHEMBL20457664 | 0.81 | ALDH1A1 (0.77) | ALDH1A1POLBBDKRB1 | |
| SCHEMBL6029674 | 0.80 | ALDH1A1 (1.00) | ALDH1A1POLBBDKRB1 | |
| SCHEMBL6403536 | 0.80 | ALDH1A1 (1.00) | ALDH1A1POLBBDKRB1 | |
| SCHEMBL15599334 | 0.77 | ALDH1A1 (0.77) | ALDH1A1POLBBDKRB1 | |
| SCHEMBL4425350 | 0.77 | ALDH1A1 (0.58) | ALDH1A1POLBBDKRB1 | |
| SCHEMBL6406112 | 0.77 | BDKRB1 (0.67) | ALDH1A1POLBBDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2895204-B1 | COMPOSITIONS TARGETING BRADYKININ RECEPTOR B1 FOR MEDICAL IMAGING OF CANCER AND OTHER DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2020-10-21 | — | — | EP | disclosed |
| US-10039846-B2 | Compositions targeting bradykinin receptor B1 for medical imaging of cancer and other disorders | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2018-08-07 | — | — | US | disclosed |
| US-20150238641-A1 | COMPOSITIONS TARGETING BRADYKININ RECEPTOR B1 FOR MEDICAL IMAGING OF CANCER AND OTHER DISORDERS | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2015-08-27 | — | — | US | disclosed |
| WO-2014040192-A1 | COMPOSITIONS TARGETING BRADYKININ RECEPTOR B1 FOR MEDICAL IMAGING OF CANCER AND OTHER DISORDERS | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238641-A1 | COMPOSITIONS TARGETING BRADYKININ RECEPTOR B1 FOR MEDICAL IMAGING OF CANCER AND OTHER DISORDERS | BDKRB1, BDKRB2, VIPR1 | ALDH1A1 4374/4885POLB 3096/4885BDKRB1 1/4885 |
| US-10039846-B2 | Compositions targeting bradykinin receptor B1 for medical imaging of cancer and other disorders | BDKRB1, BDKRB2, EDNRB | ALDH1A1 4470/4885POLB 2559/4885BDKRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.